Management of hepatitis C in patients with chronic kidney disease

Hepatitis C virus(HCV) infection is highly prevalent among chronic kidney disease(CKD) subjects under hemodialysis and in kidney transplantation(KT) recipients, being an important cause of morbidity and mortality in these patients. The vast majority of HCV chronic infections in the hemodialysis sett...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:World journal of gastroenterology : WJG 2015-01, Vol.21 (2), p.408-422
Hauptverfasser: Carvalho-Filho, Roberto J, Feldner, Ana Cristina C A, Silva, Antonio Eduardo B, Ferraz, Maria Lucia G
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 422
container_issue 2
container_start_page 408
container_title World journal of gastroenterology : WJG
container_volume 21
creator Carvalho-Filho, Roberto J
Feldner, Ana Cristina C A
Silva, Antonio Eduardo B
Ferraz, Maria Lucia G
description Hepatitis C virus(HCV) infection is highly prevalent among chronic kidney disease(CKD) subjects under hemodialysis and in kidney transplantation(KT) recipients, being an important cause of morbidity and mortality in these patients. The vast majority of HCV chronic infections in the hemodialysis setting are currently attributable to nosocomial transmission. Acute and chronic hepatitis C exhibits distinct clinical and laboratorial features, which can impact on managementand treatment decisions. In hemodialysis subjects, acute infections are usually asymptomatic and anicteric; since spontaneous viral clearance is very uncommon in this context, acute infections should be treated as soon as possible. In KT recipients, the occurrence of acute hepatitis C can have a more severe course, with a rapid progression of liver fibrosis. In these patients, it is recommended to use pegylated interferon(PEG-IFN) in combination with ribavirin, with doses adjusted according to estimated glomerular filtration rate. There is no evidence suggesting that chronic hepatitis C exhibits a more aggressive course in CKD subjects under conservative management. In these subjects, indication of treatment with PEG-IFN plus ribavirin relies on the CKD stage, rate of progression of renal dysfunction and the possibility of a preemptive transplant. HCV infection has been associated with both liver disease-related deaths and cardiovascular mortality in hemodialysis patients. Among those individuals, low HCV viral loads and the phenomenon of intermittent HCV viremia are often observed, and sequential HCV RNA monitoring is needed. Despite the poor tolerability and suboptimal efficacy of antiviral therapy in CKD patients, many patients can achieve sustained virological response, which improve patient and graft outcomes. Hepatitis C eradication before KT theoretically improves survival and reduces the occurrence of chronic graft nephropathy, de novo glomerulonephritis and post-transplant diabetes mellitus.
doi_str_mv 10.3748/wjg.v21.i2.408
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4292272</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cqvip_id>90888889504849534850484852</cqvip_id><sourcerecordid>1652412041</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-bbc84c089e3c2d77a18e2d5e1f5db475ee24bdccb98ca8ae12a0b70fc9aeb0e63</originalsourceid><addsrcrecordid>eNpVkMFP2zAUh62JCTrGlSPykUuC_Ww39gUJVbAhMe2ynS3HeUkMrVPitIj_Hnd0FfhiP73Pv_f0EXLOWSkqqa9eHrtyC7wMUEqmv5AZADcFaMmOyIwzVhVGQHVCvqX0yBgIoeCYnIBSRkg1n5GbXy66DlcYJzq0tMe1m8IUEl3QEOmuyJ1EX8LUU9-PQwyePoUm4ittQkKX8Dv52rplwrP9fUr-3t3-WfwsHn7_uF_cPBReCjkVde219EwbFB6aqnJcIzQKeauaWlYKEWTdeF8b7Z12yMGxumKtNw5rhnNxSq7fc9ebeoWNz3uNbmnXY1i58dUOLtjPnRh62w1bK8EAVJADLvcB4_C8wTTZVUgel0sXcdgky-cKJAcmeUbLd9SPQ0ojtocxnNmdd5u92-zdBrDZe_5w8XG5A_5fdAbEPrEfYvccYndgDNO7YxSTWholpP730grEG40DkPA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1652412041</pqid></control><display><type>article</type><title>Management of hepatitis C in patients with chronic kidney disease</title><source>MEDLINE</source><source>Baishideng "World Journal of" online journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Carvalho-Filho, Roberto J ; Feldner, Ana Cristina C A ; Silva, Antonio Eduardo B ; Ferraz, Maria Lucia G</creator><creatorcontrib>Carvalho-Filho, Roberto J ; Feldner, Ana Cristina C A ; Silva, Antonio Eduardo B ; Ferraz, Maria Lucia G</creatorcontrib><description>Hepatitis C virus(HCV) infection is highly prevalent among chronic kidney disease(CKD) subjects under hemodialysis and in kidney transplantation(KT) recipients, being an important cause of morbidity and mortality in these patients. The vast majority of HCV chronic infections in the hemodialysis setting are currently attributable to nosocomial transmission. Acute and chronic hepatitis C exhibits distinct clinical and laboratorial features, which can impact on managementand treatment decisions. In hemodialysis subjects, acute infections are usually asymptomatic and anicteric; since spontaneous viral clearance is very uncommon in this context, acute infections should be treated as soon as possible. In KT recipients, the occurrence of acute hepatitis C can have a more severe course, with a rapid progression of liver fibrosis. In these patients, it is recommended to use pegylated interferon(PEG-IFN) in combination with ribavirin, with doses adjusted according to estimated glomerular filtration rate. There is no evidence suggesting that chronic hepatitis C exhibits a more aggressive course in CKD subjects under conservative management. In these subjects, indication of treatment with PEG-IFN plus ribavirin relies on the CKD stage, rate of progression of renal dysfunction and the possibility of a preemptive transplant. HCV infection has been associated with both liver disease-related deaths and cardiovascular mortality in hemodialysis patients. Among those individuals, low HCV viral loads and the phenomenon of intermittent HCV viremia are often observed, and sequential HCV RNA monitoring is needed. Despite the poor tolerability and suboptimal efficacy of antiviral therapy in CKD patients, many patients can achieve sustained virological response, which improve patient and graft outcomes. Hepatitis C eradication before KT theoretically improves survival and reduces the occurrence of chronic graft nephropathy, de novo glomerulonephritis and post-transplant diabetes mellitus.</description><identifier>ISSN: 1007-9327</identifier><identifier>EISSN: 2219-2840</identifier><identifier>DOI: 10.3748/wjg.v21.i2.408</identifier><identifier>PMID: 25593456</identifier><language>eng</language><publisher>United States: Baishideng Publishing Group Inc</publisher><subject>Antiviral Agents - adverse effects ; Antiviral Agents - therapeutic use ; Cross Infection - diagnosis ; Cross Infection - drug therapy ; Cross Infection - mortality ; Cross Infection - transmission ; disease;End-stage ; Drug Therapy, Combination ; Hepatitis ; Hepatitis C, Chronic - diagnosis ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - mortality ; Hepatitis C, Chronic - transmission ; Humans ; kidney ; Kidney Transplantation - adverse effects ; Kidney Transplantation - mortality ; Renal Dialysis - adverse effects ; Renal Dialysis - mortality ; Renal Insufficiency, Chronic - diagnosis ; Renal Insufficiency, Chronic - mortality ; Renal Insufficiency, Chronic - therapy ; Review ; Risk Factors ; Treatment Outcome ; virus;Chronic</subject><ispartof>World journal of gastroenterology : WJG, 2015-01, Vol.21 (2), p.408-422</ispartof><rights>The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved. 2015</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-bbc84c089e3c2d77a18e2d5e1f5db475ee24bdccb98ca8ae12a0b70fc9aeb0e63</citedby><cites>FETCH-LOGICAL-c434t-bbc84c089e3c2d77a18e2d5e1f5db475ee24bdccb98ca8ae12a0b70fc9aeb0e63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://image.cqvip.com/vip1000/qk/84123X/84123X.jpg</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292272/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292272/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25593456$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carvalho-Filho, Roberto J</creatorcontrib><creatorcontrib>Feldner, Ana Cristina C A</creatorcontrib><creatorcontrib>Silva, Antonio Eduardo B</creatorcontrib><creatorcontrib>Ferraz, Maria Lucia G</creatorcontrib><title>Management of hepatitis C in patients with chronic kidney disease</title><title>World journal of gastroenterology : WJG</title><addtitle>World Journal of Gastroenterology</addtitle><description>Hepatitis C virus(HCV) infection is highly prevalent among chronic kidney disease(CKD) subjects under hemodialysis and in kidney transplantation(KT) recipients, being an important cause of morbidity and mortality in these patients. The vast majority of HCV chronic infections in the hemodialysis setting are currently attributable to nosocomial transmission. Acute and chronic hepatitis C exhibits distinct clinical and laboratorial features, which can impact on managementand treatment decisions. In hemodialysis subjects, acute infections are usually asymptomatic and anicteric; since spontaneous viral clearance is very uncommon in this context, acute infections should be treated as soon as possible. In KT recipients, the occurrence of acute hepatitis C can have a more severe course, with a rapid progression of liver fibrosis. In these patients, it is recommended to use pegylated interferon(PEG-IFN) in combination with ribavirin, with doses adjusted according to estimated glomerular filtration rate. There is no evidence suggesting that chronic hepatitis C exhibits a more aggressive course in CKD subjects under conservative management. In these subjects, indication of treatment with PEG-IFN plus ribavirin relies on the CKD stage, rate of progression of renal dysfunction and the possibility of a preemptive transplant. HCV infection has been associated with both liver disease-related deaths and cardiovascular mortality in hemodialysis patients. Among those individuals, low HCV viral loads and the phenomenon of intermittent HCV viremia are often observed, and sequential HCV RNA monitoring is needed. Despite the poor tolerability and suboptimal efficacy of antiviral therapy in CKD patients, many patients can achieve sustained virological response, which improve patient and graft outcomes. Hepatitis C eradication before KT theoretically improves survival and reduces the occurrence of chronic graft nephropathy, de novo glomerulonephritis and post-transplant diabetes mellitus.</description><subject>Antiviral Agents - adverse effects</subject><subject>Antiviral Agents - therapeutic use</subject><subject>Cross Infection - diagnosis</subject><subject>Cross Infection - drug therapy</subject><subject>Cross Infection - mortality</subject><subject>Cross Infection - transmission</subject><subject>disease;End-stage</subject><subject>Drug Therapy, Combination</subject><subject>Hepatitis</subject><subject>Hepatitis C, Chronic - diagnosis</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - mortality</subject><subject>Hepatitis C, Chronic - transmission</subject><subject>Humans</subject><subject>kidney</subject><subject>Kidney Transplantation - adverse effects</subject><subject>Kidney Transplantation - mortality</subject><subject>Renal Dialysis - adverse effects</subject><subject>Renal Dialysis - mortality</subject><subject>Renal Insufficiency, Chronic - diagnosis</subject><subject>Renal Insufficiency, Chronic - mortality</subject><subject>Renal Insufficiency, Chronic - therapy</subject><subject>Review</subject><subject>Risk Factors</subject><subject>Treatment Outcome</subject><subject>virus;Chronic</subject><issn>1007-9327</issn><issn>2219-2840</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkMFP2zAUh62JCTrGlSPykUuC_Ww39gUJVbAhMe2ynS3HeUkMrVPitIj_Hnd0FfhiP73Pv_f0EXLOWSkqqa9eHrtyC7wMUEqmv5AZADcFaMmOyIwzVhVGQHVCvqX0yBgIoeCYnIBSRkg1n5GbXy66DlcYJzq0tMe1m8IUEl3QEOmuyJ1EX8LUU9-PQwyePoUm4ittQkKX8Dv52rplwrP9fUr-3t3-WfwsHn7_uF_cPBReCjkVde219EwbFB6aqnJcIzQKeauaWlYKEWTdeF8b7Z12yMGxumKtNw5rhnNxSq7fc9ebeoWNz3uNbmnXY1i58dUOLtjPnRh62w1bK8EAVJADLvcB4_C8wTTZVUgel0sXcdgky-cKJAcmeUbLd9SPQ0ojtocxnNmdd5u92-zdBrDZe_5w8XG5A_5fdAbEPrEfYvccYndgDNO7YxSTWholpP730grEG40DkPA</recordid><startdate>20150114</startdate><enddate>20150114</enddate><creator>Carvalho-Filho, Roberto J</creator><creator>Feldner, Ana Cristina C A</creator><creator>Silva, Antonio Eduardo B</creator><creator>Ferraz, Maria Lucia G</creator><general>Baishideng Publishing Group Inc</general><scope>2RA</scope><scope>92L</scope><scope>CQIGP</scope><scope>W91</scope><scope>~WA</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20150114</creationdate><title>Management of hepatitis C in patients with chronic kidney disease</title><author>Carvalho-Filho, Roberto J ; Feldner, Ana Cristina C A ; Silva, Antonio Eduardo B ; Ferraz, Maria Lucia G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-bbc84c089e3c2d77a18e2d5e1f5db475ee24bdccb98ca8ae12a0b70fc9aeb0e63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Antiviral Agents - adverse effects</topic><topic>Antiviral Agents - therapeutic use</topic><topic>Cross Infection - diagnosis</topic><topic>Cross Infection - drug therapy</topic><topic>Cross Infection - mortality</topic><topic>Cross Infection - transmission</topic><topic>disease;End-stage</topic><topic>Drug Therapy, Combination</topic><topic>Hepatitis</topic><topic>Hepatitis C, Chronic - diagnosis</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - mortality</topic><topic>Hepatitis C, Chronic - transmission</topic><topic>Humans</topic><topic>kidney</topic><topic>Kidney Transplantation - adverse effects</topic><topic>Kidney Transplantation - mortality</topic><topic>Renal Dialysis - adverse effects</topic><topic>Renal Dialysis - mortality</topic><topic>Renal Insufficiency, Chronic - diagnosis</topic><topic>Renal Insufficiency, Chronic - mortality</topic><topic>Renal Insufficiency, Chronic - therapy</topic><topic>Review</topic><topic>Risk Factors</topic><topic>Treatment Outcome</topic><topic>virus;Chronic</topic><toplevel>online_resources</toplevel><creatorcontrib>Carvalho-Filho, Roberto J</creatorcontrib><creatorcontrib>Feldner, Ana Cristina C A</creatorcontrib><creatorcontrib>Silva, Antonio Eduardo B</creatorcontrib><creatorcontrib>Ferraz, Maria Lucia G</creatorcontrib><collection>中文科技期刊数据库</collection><collection>中文科技期刊数据库-CALIS站点</collection><collection>中文科技期刊数据库-7.0平台</collection><collection>中文科技期刊数据库-医药卫生</collection><collection>中文科技期刊数据库- 镜像站点</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>World journal of gastroenterology : WJG</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carvalho-Filho, Roberto J</au><au>Feldner, Ana Cristina C A</au><au>Silva, Antonio Eduardo B</au><au>Ferraz, Maria Lucia G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Management of hepatitis C in patients with chronic kidney disease</atitle><jtitle>World journal of gastroenterology : WJG</jtitle><addtitle>World Journal of Gastroenterology</addtitle><date>2015-01-14</date><risdate>2015</risdate><volume>21</volume><issue>2</issue><spage>408</spage><epage>422</epage><pages>408-422</pages><issn>1007-9327</issn><eissn>2219-2840</eissn><abstract>Hepatitis C virus(HCV) infection is highly prevalent among chronic kidney disease(CKD) subjects under hemodialysis and in kidney transplantation(KT) recipients, being an important cause of morbidity and mortality in these patients. The vast majority of HCV chronic infections in the hemodialysis setting are currently attributable to nosocomial transmission. Acute and chronic hepatitis C exhibits distinct clinical and laboratorial features, which can impact on managementand treatment decisions. In hemodialysis subjects, acute infections are usually asymptomatic and anicteric; since spontaneous viral clearance is very uncommon in this context, acute infections should be treated as soon as possible. In KT recipients, the occurrence of acute hepatitis C can have a more severe course, with a rapid progression of liver fibrosis. In these patients, it is recommended to use pegylated interferon(PEG-IFN) in combination with ribavirin, with doses adjusted according to estimated glomerular filtration rate. There is no evidence suggesting that chronic hepatitis C exhibits a more aggressive course in CKD subjects under conservative management. In these subjects, indication of treatment with PEG-IFN plus ribavirin relies on the CKD stage, rate of progression of renal dysfunction and the possibility of a preemptive transplant. HCV infection has been associated with both liver disease-related deaths and cardiovascular mortality in hemodialysis patients. Among those individuals, low HCV viral loads and the phenomenon of intermittent HCV viremia are often observed, and sequential HCV RNA monitoring is needed. Despite the poor tolerability and suboptimal efficacy of antiviral therapy in CKD patients, many patients can achieve sustained virological response, which improve patient and graft outcomes. Hepatitis C eradication before KT theoretically improves survival and reduces the occurrence of chronic graft nephropathy, de novo glomerulonephritis and post-transplant diabetes mellitus.</abstract><cop>United States</cop><pub>Baishideng Publishing Group Inc</pub><pmid>25593456</pmid><doi>10.3748/wjg.v21.i2.408</doi><tpages>15</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1007-9327
ispartof World journal of gastroenterology : WJG, 2015-01, Vol.21 (2), p.408-422
issn 1007-9327
2219-2840
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4292272
source MEDLINE; Baishideng "World Journal of" online journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection
subjects Antiviral Agents - adverse effects
Antiviral Agents - therapeutic use
Cross Infection - diagnosis
Cross Infection - drug therapy
Cross Infection - mortality
Cross Infection - transmission
disease
End-stage
Drug Therapy, Combination
Hepatitis
Hepatitis C, Chronic - diagnosis
Hepatitis C, Chronic - drug therapy
Hepatitis C, Chronic - mortality
Hepatitis C, Chronic - transmission
Humans
kidney
Kidney Transplantation - adverse effects
Kidney Transplantation - mortality
Renal Dialysis - adverse effects
Renal Dialysis - mortality
Renal Insufficiency, Chronic - diagnosis
Renal Insufficiency, Chronic - mortality
Renal Insufficiency, Chronic - therapy
Review
Risk Factors
Treatment Outcome
virus
Chronic
title Management of hepatitis C in patients with chronic kidney disease
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T15%3A30%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Management%20of%20hepatitis%20C%20in%20patients%20with%20chronic%20kidney%20disease&rft.jtitle=World%20journal%20of%20gastroenterology%20:%20WJG&rft.au=Carvalho-Filho,%20Roberto%20J&rft.date=2015-01-14&rft.volume=21&rft.issue=2&rft.spage=408&rft.epage=422&rft.pages=408-422&rft.issn=1007-9327&rft.eissn=2219-2840&rft_id=info:doi/10.3748/wjg.v21.i2.408&rft_dat=%3Cproquest_pubme%3E1652412041%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1652412041&rft_id=info:pmid/25593456&rft_cqvip_id=90888889504849534850484852&rfr_iscdi=true